Professor CHIN-FU HSAIO
Mail : chinfu@nhri.org.tw
Tel : 03-737246166 ext. 3610
1997 Ph.D. in Statistics, University of Wisconsin-Madison, Wisconsin, U.S.A.
1989 M.S. in Mathematics, National Central University, Taiwan
1987 B.S. in Mathematics, National Central University, Taiwan
2014.08-present Institute of Population Health Sciences, National Health Research Institutes, Taiwan, Deputy Director
2012.08-present National Yang Ming University, Taiwan, Adjunct Professor
2011.10-present Institute of Population Health Sciences, National Health Research Institutes, Taiwan
Investigator
2011.08- present National Chiao Tung University, Taiwan Adjunct Professor
2006.02- present National Taiwan University, Taiwan Adjunct Professor
2011.01-2014.07 Division of Clinical Trial Statistics, Institute of Population Health Sciences, National Health Research Institutes, Taiwan Director
2004.09-2011.09 Division of Biostatistics and Bioinformatics, Institute of Population Health Sciences, National Health Research Institutes, Taiwan Associate Investigator
2001.02-2004.09 Division of Biostatistics and Bioinformatics, National Health Research Institutes, Taiwan Assistant Investigator
1.Liu JT, Tsou HH*. Lan KKG, Chen CT, Lai YH, Chang WJ, Tzeng CS, Hsiao CF*.(2016). Assessing the consistency of the treatment effect under the discrete random effects model in multiregional clinical trials, accepted by Statistics in Medicine.
2.Chie WC, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-KadhimiG, Heaton N, Calara J, Collins P, Caddick K, Costantini A, Vilgrain V,Chiang C. (2016). Differences in health-related quality of life between European and Asian patients with primary liver cancer, accepted by Asia-Pacific Journal of Clinical Oncology.
3.Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. (2016). A phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable
gastric adenocarcinoma: The TCOG 3211 clinical trial, Medicine, 95(3):e2565.
4.Chen KY, Hsiao CF, Chang GC, Tsai YH, Su WC, Chen YM, Huang MS, Tsai FY, Jiang SS, Chang IS, Chen CY, Hsiung CA, Chen CJ, Yang PC. (2015). Estrogen receptor gene polymorphisms and lung adenocarcinoma risk
in never-smoking women, Journal of Thoracic Oncology, 10(10):1413-20.
5.Wu YJ, Chen CT, Tsou HH, Hsiao CF. (2015). Evaluating the relative cost of a targeted design versus an untargeted design for randomized clinical trials, Drug Designing: Open Access, 4:120.
6.Chie WC, Yu F, Li M, Baccaglini L, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhimi G, Heaton N, Calara J, Collins P, Caddick K, Costantini A, Vilgrain V, Chiang C. (2015). Quality of life changes in patients undergoing treatment for hepatocellular carcinoma, Qual Life Res, 24(10):2499-506.
7.Chiang C, Hsiao CF, Liu JP. (2014) Sample size determination for individual bioequivalence inference. PLoS ONE, 9(10):e109746. (Co-first author)
8.Yoon S, Assimes TL, Quertermous T, Hsiao CF, Chunag LM, Hwu CM, Rajaratnam B, Olshen RA. (2014). Insulin resistance: regression and clustering, PLoS One, 9(6):e94129.
9.Chiang C, Hsiao CF, Liu JP. (2014). Sample size determination for withindevice precision, Journal of Chemometrics, 28(3):202-211. (Co-first author)
10.Wang LW, Hsiao CF, Chen WT, Lee HH, Lin TC, Chen HC, Chen HH, Chien CR, Lin TY, Liu TW. (2014). Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: A phase II TCOG study, Journal of Surgical Oncology, 109(6):580-585.
